ENDRA Life Sciences Inc.
NDRA
$3.61
$0.23997.12%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 6.83M | 7.63M | 4.85M | 5.63M | 5.71M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 9.51M | 10.82M | 7.98M | 9.60M | 10.36M |
| Operating Income | -9.51M | -10.82M | -7.98M | -9.60M | -10.36M |
| Income Before Tax | -9.77M | -11.51M | -8.82M | -9.57M | -9.89M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -9.77 | -11.51 | -8.82 | -9.57 | -9.89 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -9.77M | -11.51M | -8.82M | -9.57M | -9.89M |
| EBIT | -9.51M | -10.82M | -7.98M | -9.60M | -10.36M |
| EBITDA | -9.46M | -10.77M | -7.92M | -9.52M | -10.26M |
| EPS Basic | -162.07 | -160.21 | -152.52 | -142.99 | -- |
| Normalized Basic EPS | -101.29 | -100.13 | -95.33 | -89.37 | -- |
| EPS Diluted | -162.07 | -160.21 | -152.52 | -142.99 | -- |
| Normalized Diluted EPS | -101.29 | -100.13 | -95.33 | -89.37 | -- |
| Average Basic Shares Outstanding | 1.36M | 802.00K | 262.40K | 15.60K | -- |
| Average Diluted Shares Outstanding | 1.36M | 802.00K | 262.40K | 15.60K | -- |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |